63
Participants
Start Date
February 28, 2009
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
Sutent
Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
Virginia Oncology Associates, Norfolk
Cancer Centers of North Carolina, Raleigh
Cancer Centers of the Carolinas, Greenville
Ocala Oncology Center, Ocala
Cancer Centers of Florida, P.A., Ocoee
Minnesota Oncology Hematology, P.A., Minneapolis
Texas Cancer Center of Mesquite, Mesquite
Methodist Charlton Cancer Ctr., Dallas
Texas Oncology - Arlington South, Arlington
Texas Oncology, P.A. - Bedford, Bedford
Texas Oncology Cancer Care and Research Center, Waco
Yakima Valley Mem Hosp/North Star Lodge, Yakima
Willamette Valley Cancer Institute and Research Center, Eugene
Collaborators (1)
Pfizer
INDUSTRY
US Oncology Research
INDUSTRY